New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

Viking Therapeutics (VKTX) stock receives a Neutral rating at Goldman Sachs due to intense competition in its targeted ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

Goldman Sachs analyst Richard Law initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $30 price target The company’s ...

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.

The therapy, a dual GLP-1/GIP agonist, has shown promise in Phase 2 trials, demonstrating potency and safety. However, Goldman Sachs highlighted the high barriers to entry in the obesity market ...